The Emergence Of IO
The Emergence Of IO
$131.00
Immuno-oncology: spurred by the approval of first-generation checkpoint inhibitors in 2014, this important market has continued to grow exponentially, as deals are made not only around checkpoint inhibitors themselves, but also for related molecules and technologies to be used in synergy with them. Examine the origins of this important and growing area in this essential In Vivo report.
Author: Swarna Mehrotra, Oded Ben-Joseph, Ellen Baron
Publisher: InVivo
- Description
Follow the origins of the immuno-oncology market in this examination of the deals and activities surrounding this important area. Such activity has resulted in a frenzy among big pharma and biotech to partner with or acquire those companies developing IO assets, making IO therapeutics the main driver in the competitive dealmaking area of oncology. Examine the deals and events from the first IO checkpoint inhibitor approvals (Merck & Co. Inc.’s Keytruda and Bristol-Myers Squibb Co.’s Opdivo, both in 2014) leading up to the present, where IO therapeutics continue to lead the competitive oncology area with emergent technologies like CAR-T therapies, and more.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Datamonitor Healthcare Strategy: Gene Therapy Commercialization – Opportunities... 
Sign up to the